Literature DB >> 6428308

In vitro comparison of Pseudomonas aeruginosa isolates with various susceptibilities to aminoglycosides and ten beta-lactam antibiotics.

D H Wu, A L Baltch, R P Smith.   

Abstract

Susceptibilities of 98 clinical isolates of Pseudomonas aeruginosa, including 33 strains with known mechanisms of amikacin resistance, were tested by the agar dilution method against 10 beta-lactam drugs. Ceftazidime, imipenem, and cefsulodin had the greatest activity, regardless of the aminoglycoside susceptibilities. The strains which were highly resistant to amikacin appeared to be less susceptible to some beta-lactam drugs, especially if their resistance was related to amikacin-inactivating enzymes; statistical significance, however, was observed for aztreonam only.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428308      PMCID: PMC185558          DOI: 10.1128/AAC.25.4.488

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  The nephrotoxicity of antimicrobial agents (second of three parts).

Authors:  G B Appel; H C Neu
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

2.  Comparative inhibitory and bactericidal activities of moxalactam and seven other antibiotics against 520 clinical isolates including 65 multi-drug resistant strains.

Authors:  N T Sutphen; A L Baltch; J V Conroy; M C Hammer; R P Smith
Journal:  J Antimicrob Chemother       Date:  1982-07       Impact factor: 5.790

3.  Treatment of serious infections with moxalactam.

Authors:  B S Ribner; R Raeder; T M Becker; E H Freimer
Journal:  Am J Med       Date:  1983-03       Impact factor: 4.965

4.  Pseudomonas aeruginosa bacteremia: a clinical study of 75 patients.

Authors:  A L Baltch; P E Griffin
Journal:  Am J Med Sci       Date:  1977 Sep-Oct       Impact factor: 2.378

5.  Pseudomonas aeruginosa bacteremia: susceptibility of 100 blood culture isolates to seven antimicrobial agents and its clinical significance.

Authors:  A L Baltch; M Hammer; R P Smith; N Sutphen
Journal:  J Lab Clin Med       Date:  1979-08

6.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

7.  In vitro comparison of N-formimidoyl thienamycin (MK0787) and Azlocillin with three aminoglycosides and ticarcillin against Pseudomonas aeruginosa.

Authors:  A J Matzkowitz; A L Baltch; R P Smith; N T Sutphen; M C Hammer; J V Conroy
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

8.  Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

9.  Cefsulodin: antibacterial activity and tentative interpretive zone standards for the disk susceptibility test.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

10.  Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

Authors:  L C Preheim; R G Penn; C C Sanders; R V Goering; D K Giger
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

View more
  3 in total

Review 1.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

2.  Isolation and characterization of a transposon-induced cytotoxin-deficient mutant of Pseudomonas aeruginosa.

Authors:  L H Bopp; A L Baltch; M C Hammer; M A Franke; R P Smith; F Lutz
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

3.  In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.

Authors:  J Fung-Tomc; E Huczko; B Kolek; C Thater; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.